33.76
6.26%
1.99
Dopo l'orario di chiusura:
33.40
-0.36
-1.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$31.77
Aprire:
$32.06
Volume 24 ore:
1.66M
Relative Volume:
0.98
Capitalizzazione di mercato:
$4.17B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-7.9623
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
+10.91%
1M Prestazione:
-5.65%
6M Prestazione:
+18.83%
1 anno Prestazione:
+33.02%
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
33.76 | 4.17B | 692.26M | -512.41M | -274.36M | -4.24 |
TMO
Thermo Fisher Scientific Inc
|
532.02 | 203.50B | 42.37B | 6.14B | 7.78B | 15.95 |
DHR
Danaher Corp
|
234.84 | 169.62B | 23.74B | 3.89B | 4.98B | 5.24 |
A
Agilent Technologies Inc
|
135.69 | 38.75B | 6.51B | 1.29B | 1.37B | 4.42 |
IQV
Iqvia Holdings Inc
|
197.39 | 35.83B | 15.32B | 1.41B | 1.96B | 7.62 |
IDXX
Idexx Laboratories Inc
|
415.53 | 34.03B | 3.84B | 866.24M | 792.60M | 10.37 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
2024-06-03 | Ripresa | Jefferies | Buy |
2024-04-24 | Ripresa | Craig Hallum | Buy |
2023-12-14 | Iniziato | Guggenheim | Neutral |
2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2023-09-28 | Iniziato | Bernstein | Outperform |
2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2023-07-05 | Ripresa | JP Morgan | Overweight |
2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
2023-05-05 | Iniziato | UBS | Buy |
2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-10-19 | Iniziato | Craig Hallum | Buy |
2022-10-06 | Iniziato | Stephens | Overweight |
2022-08-25 | Iniziato | Credit Suisse | Outperform |
2022-06-03 | Iniziato | Piper Sandler | Overweight |
2022-04-28 | Ripresa | BTIG Research | Buy |
2022-02-24 | Reiterato | Canaccord Genuity | Buy |
2022-02-24 | Reiterato | Citigroup | Buy |
2022-02-24 | Reiterato | Cowen | Outperform |
2022-02-24 | Reiterato | Morgan Stanley | Overweight |
2022-02-24 | Reiterato | SVB Leerink | Outperform |
2022-02-24 | Reiterato | Stifel | Buy |
2022-02-24 | Reiterato | Wells Fargo | Overweight |
2021-10-15 | Ripresa | Cowen | Outperform |
2021-06-15 | Iniziato | Raymond James | Mkt Perform |
2021-06-03 | Iniziato | Goldman | Buy |
2021-05-25 | Iniziato | Wells Fargo | Overweight |
2021-01-11 | Iniziato | Stifel | Buy |
2020-09-09 | Iniziato | Morgan Stanley | Overweight |
2020-06-12 | Iniziato | BTIG Research | Buy |
2020-02-21 | Iniziato | Guggenheim | Buy |
2020-01-07 | Iniziato | Citigroup | Buy |
2019-08-07 | Reiterato | Canaccord Genuity | Buy |
2019-04-16 | Iniziato | Canaccord Genuity | Buy |
2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2019-02-28 | Reiterato | BofA/Merrill | Neutral |
2018-10-29 | Iniziato | BofA/Merrill | Neutral |
2018-10-29 | Iniziato | JP Morgan | Overweight |
2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Piper Sandler maintains Overweight on Guardant Health stock By Investing.com - Investing.com UK
GHGuardant Health, Inc. Latest Stock News & Market Updates - StockTitan
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Guardant Health, Inc. (NASDAQ:GH) Sees Large Decline in Short Interest - MarketBeat
Why Guardant Health, Inc. (NASDAQ:GH) Could Be Worth Watching - Simply Wall St
Natera: Poised For A Great Future But I'd Wait For A Pullback (NASDAQ:NTRA) - Seeking Alpha
Sheffield United takeover completed by COH Sports - Reuters
FDA approves blood-based test screens for colon cancer - MSN
Geode Capital Management LLC Purchases 29,686 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health director Tariq Musa sells $4,042 in common stock - Investing.com India
Guardant Health Partners with MiBA to Transform Cancer Care with AI-Powered Precision Oncology - StockTitan
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Franklin Resources Inc. - MarketBeat
Guardant Health director Tariq Musa sells $4,042 in common stock By Investing.com - Investing.com South Africa
Meaningful Insights Biotech Analytics and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care - Marketscreener.com
Guardant Health and COTA partner in advanced oncology R&D - TipRanks
Guardant Health Partners with COTA to Revolutionize Cancer Drug Development Through AI-Powered Data - StockTitan
Y Intercept Hong Kong Ltd Sells 38,937 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health teams up with Boehringer for cancer test By Investing.com - Investing.com Australia
Guardant Health teams up with Boehringer for cancer test - Investing.com
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer - Business Wire
Guardant Health Partners with Boehringer Ingelheim on Breakthrough Lung Cancer Diagnostic Test - StockTitan
Insider Selling: Guardant Health, Inc. (NASDAQ:GH) Director Sells 2,320 Shares of Stock - MarketBeat
Guardant Health director Tariq Musa sells $81,200 in stock - Investing.com
681,074 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Lord Abbett & CO. LLC - MarketBeat
XTX Topco Ltd Has $409,000 Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Receives $40.60 Consensus Target Price from Analysts - MarketBeat
(GH) Trading Report - Stock Traders Daily
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal - The Eastern Progress Online
Verition Fund Management LLC Buys 25,900 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium - The Bakersfield Californian
Wellington Management Group LLP Purchases 6,618,785 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health to Showcase Breakthrough Liquid Biopsy Research at Major Breast Cancer Symposium - StockTitan
Pier Capital LLC Buys 42,575 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Shares Bought by Two Sigma Advisers LP - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Temasek Holdings Private Ltd Reduces Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Charles Schwab Investment Management Inc. Has $23.01 Million Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Investors in Guardant Health (NASDAQ:GH) from three years ago are still down 61%, even after 8.6% gain this past week - Yahoo Finance
Strong week for Guardant Health (NASDAQ:GH) shareholders doesn't alleviate pain of three-year loss - Simply Wall St
Guardant Health stock soars to 52-week high of $37.04 By Investing.com - Investing.com Nigeria
Guardant Health Inc (GH) Shares Up 4.11% on Dec 4 - GuruFocus.com
Guardant Health stock soars to 52-week high of $37.04 - Investing.com
Guardant Health Stock Flashing Surefire ‘Buy’ Signal - Forbes
The Manufacturers Life Insurance Company Sells 28,746 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (FRA:5GH) Shares Outstanding (EOP) : 123.2 Mil (As of Sep. 2024) - GuruFocus.com
Liquid Biopsy Market Is Booming So Rapidly with Major Giants - openPR
Guardant awarded nearly $293M in false ad trial against Natera - MedTech Dive
Erste Asset Management GmbH Buys New Stake in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Fred Alger Management LLC Sells 43,039 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
GH (Guardant Health) EBITDA per Share : $-3.86 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health (STU:5GH) EPS (Diluted) : €-3.89 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Guardant Health Inc Azioni (GH) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Kalia Kumud | Chief Information Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
2,690 |
0 |
21,098 |
Freeman Chris | Chief Commercial Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
3,595 |
0 |
35,852 |
EAGLE CRAIG | Chief Medical Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
3,381 |
0 |
27,343 |
Chudova Darya | Chief Technology Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
3,006 |
0 |
57,786 |
Bell Michael Brian | Chief Financial Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
2,084 |
0 |
27,772 |
Talasaz AmirAli | Co-Chief Executive Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
11,462 |
0 |
2,215,894 |
Talasaz AmirAli | Co-Chief Executive Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
94,555 |
0 |
2,304,640 |
Eltoukhy Helmy | Co-Chief Executive Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
11,462 |
0 |
2,315,728 |
Eltoukhy Helmy | Co-Chief Executive Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
94,555 |
0 |
2,404,474 |
Krognes Steve E. | Director |
Dec 31 '24 |
Option Exercise |
0.00 |
155 |
0 |
10,220 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):